Table I.
Clinical assessment of genotyped subjects
| WT non-AD | WT AD | FLG non-AD | FLG AD | |
|---|---|---|---|---|
| TEWL and tape-stripping group | ||||
| No. | 18 | 46 | 8 | 12 |
| Age (y [range]) | 28 (19-59) | 35 (18-76) | 28 (19-58) | 35 (22-57) |
| Male/female sex | 8/10 | 16/30 | 4/4 | 5/7 |
| SASSAD ± SD | NA | 11 ± 9.3 | NA | 12 ± 7.5 |
| IgE ± SD (IU/mL)∗ | 63 ± 63 (n = 14) | 678 ± 1374 (n = 46) | 33 ± 47 (n = 6) | 443 ± 892 (n = 12) |
| Asthma | 2 (11%) | 15 (33%) | 2 (25%) | 5 (42%) |
| Hay fever† | 1 (6%) | 27 (59%) | 1 (13%) | 4 (33%) |
| Suction blister flow cytometry group | ||||
| No. | 8 | 7 | 4 | 8 |
| Age (y [range]) | 31 (20-55) | 42 (27-76) | 21 (19-25) | 37 (27-57) |
| Male/female sex | 3/5 | 3/4 | 3/1 | 3/5 |
| SASSAD ± SD | NA | 6 ± 4 | NA | 8 ± 3 |
| Suction blister immunostaining group | ||||
| No. | 4 | 3 | 5 | 4 |
| Age (y [range]) | 34 (21-51) | 21 (20-21) | 35 (20-54) | 40 (22-56) |
| Male/female sex | 3/1 | 2/1 | 4/1 | 2/2 |
| SASSAD ± SD | NA | 12 ± 8 | NA | 15 ± 8 |
NA, Not applicable; SASSAD, Six-Area, Six-Sign Atopic Dermatitis score.
∗
P = .0001, AD versus non-AD.
†
P = .0001, AD versus non-AD.